All In Biotech

Drug Trial Radar · NCT04402957

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

61

Actual

Start

Oct 14, 2020

Primary completion

May 27, 2021

Study completion Jun 2, 2022

Sponsor

Lead sponsor
Arch Biopartners Inc.Industry
Sponsor type
Industry
First posted
May 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy (RRT) on Day 28. The need for continued RRT at Day 28 will be defined as either dialysis in the past 3 days (Day 26, 27, or 28) or an eGFR on Day 28 \<10 mL/min/1.73 m2.

Conditions

  • COVID
  • Severe Acute Respiratory Syndrome
  • Sars-CoV2
  • Acute Kidney Injury
  • Acute Respiratory Distress Syndrome

Interventions

  • LSALT peptideDrug

    LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.

  • PlaceboDrug

    0.9% saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per Protocol AB002 - Version 1, Dated 09JUNE2020)Time frame: 28 days

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • VA San Diego Healthcare System

    San Diego, California

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • LSU Health Shreveport

    Shreveport, Louisiana

  • University of Calgary - Foothills Medical Centre

    Calgary, Alberta, Canada

  • University of Calgary - Peter Lougheed Centre

    Calgary, Alberta, Canada

  • Ankara City Hospital

    Ankara, Turkey (Türkiye)

  • Istanbul University Cerrahpasa

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.